Fludarabine monophosphate

Phase 2Small molecule

SSt. Petersburg State Pavlov Medical University

Fludarabine monophosphate is one of 172 small molecule programs targeting Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

171

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

MyelofibrosisActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

OsteopetrosisActive, not recruiting

Bone Marrow Failure SyndromeActive, not recruiting

LeukemiaPhase 1/Phase 2

Active, not recruiting

MyelofibrosisPhase 1/Phase 2

Active, not recruiting

Bone Marrow TransplantationPhase 2

Active, not recruiting

Sickle Cell DiseasePhase 2

Active, not recruiting

OsteopetrosisPhase 2/Phase 3

Active, not recruiting

Bone Marrow Failure SyndromePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

11 2

Idamycin

Pfizer

Phase 3

10 3

Neoral

Novartis

Phase 3

9 4

Oncovin

Eli Lilly

Phase 3

9 5

Novantrone

Pfizer

Phase 3

8 6

Leukine

Sanofi

Phase 3

7 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

15 8

Rayos

RRoxane Laboratories

Phase 3

14 9

Busulfex

Akero Therapeutics

Phase 3

13 10

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transplantation2 trials

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Completed·IIvan S Moiseev·Phase 2·NCT02294552·200 enrolled

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01572662·201 enrolled

Sickle Cell Disease2 trials

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

Terminated·NNationwide Children's Hospital·Phase 2·NCT01279616·8 enrolled

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

Completed·EEmory University·Phase 2·NCT02757885·10 enrolled

Leukemia1 trial

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Completed·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT02799147·27 enrolled

Trial1 trial

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Terminated·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT02627573·32 enrolled

Myelofibrosis1 trial

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

Completed·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT02806375·20 enrolled

3 more indications

Bone Marrow Transplantation1 trial

HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen

Unknown status·NNational Guard Health Affairs·Phase 2·NCT02776202·15 enrolled

Bone Marrow Failure Syndrome1 trial

Stem Cell Transplant for Bone Marrow Failure Syndromes

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00176878·10 enrolled

Osteopetrosis1 trial

Allogeneic Transplantation For Severe Osteopetrosis

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00775931·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Fludarabine monophosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludarabine monophosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludarabine monophosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Petersburg State Pavlov Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSt. Petersburg State Pavlov Medical University

Fludarabine monophosphate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transplantation2 trials

Sickle Cell Disease2 trials

Leukemia1 trial

Trial1 trial

Myelofibrosis1 trial

Bone Marrow Transplantation1 trial

Bone Marrow Failure Syndrome1 trial

Osteopetrosis1 trial

References

Drug Info

Quick Facts

Related News